BTO-1 is a Polo-like kinase (Plk) inhibitor. BTO-1 is primarily used for phosphorylation and dephosphorylation applications.

Product information

CAS Number: 40647-02-7

Molecular Weight: 264.22

Formula: C9H4N4O4S

Chemical Name: 5-cyano-7-nitro-3-oxo-1, 3-benzothiazole-2-carboxamide

Smiles: NC(=O)C1SC2C(=CC(=CC=2[N+]([O-])=O)C#N)N=1=O

InChiKey: FKRBAXZAJBBIAJ-UHFFFAOYSA-N

InChi: InChI=1S/C9H4N4O4S/c10-3-4-1-5-7(6(2-4)13(16)17)18-9(8(11)14)12(5)15/h1-2H,(H2,11,14)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

BTO-1 (50 μM; 4 hours; U20S cells) results in monopolar spindles in a comparable fraction of mitotic cells. BTO-1(20 μM; 1 hour; PTK cells) shows a dose-dependent reduction in phospho-Cdc25C. BTO-1(25 μM; 1 hour; PTK cells) shows about 20 % reduction in H3 phosphorylation compared to control cells. BTO-1 in HeLa cells results in a blockage of Rho and Rho-GEF recruitment, which is essential for the assembly of a functional contractile ring.

Products are for research use only. Not for human use.